Skip to main content

Eli Lilly — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

163
Companies
$12.0B
Total invested
$90.8M
Avg. check
21
Industries
Biotechnology 21Health Care 14Medical 10Therapeutics 8Life Science 5Pharmaceutical 4+15 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 163
LTZ Therapeutics
May 2026

LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.

Biotechnology · San Francisco$38.0M Venture - Series Unknown
Cabaletta Bio
May 2026

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

Biotechnology · Philadelphia$150.0M Post-IPO Equity
AbCellera
May 2023

AbCellera is an antibody discovery and development company that develops antibody therapeutics to improve patient outcomes.

Biotechnology · Vancouver$515.8M Grant
Remedium Bio
May 2026

Remedium Bio is a gene therapy company focused on the development of highly innovative treatments for a broad range of diseases.

Biotechnology · Needham$1.5M Venture - Series Unknown
Seraxis
May 2025

Seraxis is a privately owned biotechnology company.

Biotechnology · GermantownGrant
Stylus Medicine
May 2025

Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders.

Biotechnology · Cambridge$85.0M Series A
Incyclix Bio
April 2026

Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.

Biotechnology · Durham$5.0M Series B
Iterative Health
April 2026

Iterative Health develops technology that can benefit patients anywhere, regardless of socioeconomic or geographic barriers.

Artificial Intelligence (AI) · Cambridge$77.0M Series C
Grove Biopharma
April 2025

Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges.

Analytics · Chicago$30.0M Series A
Trans Solutions Research and Resource Center
March 2025

Trans Solutions Research and Resource Center empowers transgender and gender communities.

Communities · Indianapolis$15K Grant
Jaguar Gene Therapy
March 2022

Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.

Biotechnology · Lake ForestVenture - Series Unknown
Augustine Therapeutics
March 2025

Augustine Therapeutics is discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases

Biopharma · Leuven$83.9M Series A
Flare Therapeutics
March 2023

Flare Therapeutics is a biotech startup that creates precision therapies for cancer and other disorders by targeting transcription factors.

Biopharma · Cambridge$123.0M Series B
Crossbow Therapeutics
March 2026

Crossbow Therapeutics is a biotech company that develops targeted therapies to address cancer antigens.

Biotechnology · Cambridge$77.0M Series B
Maxion Therapeutics
March 2025

Maxion Therapeutics helps in learning transformative therapies.

Information Technology · Cambridge$75.3M Series A
Insilico Medicine
March 2025

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.

Artificial Intelligence (AI) · Cambridge$123.0M Series E
Zephyr AI
March 2024

Zephyr AI is a healthcare technology company that reshapes traditional approaches to drug discovery and precision medicine.

Analytics · Fairfax Station$111.0M Series A
IgGenix
February 2023

IgGenix is a biotechnology company.

Biotechnology · San Francisco$40.0M Series B
Blacksmith Medicines
February 2024

Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology.

Biotechnology · San Diego$3.3M Grant
Arkuda Therapeutics
February 2022

Arkuda Therapeutics is a pharmaceutical company.

Biotechnology · Cambridge$64.0M Series B
Trogenix
October 2025

Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.

Biotechnology · Edinburgh$94.1M Series A
Dualitas Therapeutics
September 2025

Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders

Biotechnology · San Francisco$65.0M Series A
Syndeio Biosciences
May 2025

Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.

Biotechnology · Indianapolis$90.0M Venture - Series Unknown
Therini Bio
May 2025

Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.

Biotechnology · San Francisco$39.0M Series A

Where Eli Lilly invests

Biotechnology21
Health Care14
Medical10
Therapeutics8
Life Science5
Pharmaceutical4

About Eli Lilly's portfolio

How many companies has Eli Lilly invested in?

Eli Lilly has invested in 163 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Eli Lilly invest in?

Eli Lilly's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 21 different industry categories.

What is Eli Lilly's largest investment?

Among tracked funding rounds, AbCellera received $515.8M in a Grant round. Eli Lilly's total known invested capital is $12.0B.

What is the average investment size for Eli Lilly?

Eli Lilly's average investment size is $90.8M across its portfolio of 163 companies.

What are Eli Lilly's most recent investments?

Recent Eli Lilly portfolio additions include LTZ Therapeutics, Cabaletta Bio, AbCellera, Remedium Bio, Seraxis. These companies were founded in 2020 or later.

Reach the founders behind these 163 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →